drugset / Trial / NCT02971891

A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

NCT02971891

Phase 3 Completed 484 enrolled Maruho Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy and safety of six (6) weeks of once daily application of Furosemide Topical Gel 0.125% (CLS006) compared to vehicle in subjects ≥ 2 years of age with nongenital cutaneous common warts (verruca vulgaris).

Timeline

Start
2017-01
Primary completion
2018-04-16
Completion
2018-07-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Furosemide Other / unclassified 0.125 % Topical

Indications